In Ovo Vaccination Technology  *The authors are employees and consultants of Embrex, Inc., which disclaims responsibility for any private publication of its personnel. The views expressed herein do not necessarily reflect the views of Embrex, Inc. or its management.

Ricks, C. A.; Avakian, Alan P.; Bryan, Thomas; Gildersleeve, R. P.; Haddad, Eid E.; Ильич, Рубинский Юрий; S, King; Murray, Leonie; Phelps, P.; Poston, R M; Whitfill, Craig E.; Williams, Chris

doi:10.1016/s0065-3519(99)80037-8

Cited by 81 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ideal vaccines produce complete protection irrespective of the maternal antibody status of chicks when administered either in ovo or on the day of hatch (24,74 to broilers with maternal antibodies (24,43,74). The amount of antibody in the vaccine formula does not neutralize the virus but is sufficient to delay its onset of replication, as compared to the same virus used without antiserum (41).…”

Section: Maternal Immunity and In Ovo Vaccinationmentioning

confidence: 99%

Comparison ofin ovoand post‐hatch vaccination with particular reference to infectious bursal disease. A review

Negash

Al-Garib

Gruys

2004

Veterinary Quarterly

View full text Add to dashboard Cite

Section: Maternal Immunity and In Ovo Vaccinationmentioning

confidence: 99%

Comparison ofin ovoand post‐hatch vaccination with particular reference to infectious bursal disease. A review

Negash

Al-Garib

Gruys

2004

Veterinary Quarterly

View full text Add to dashboard Cite

“…Experimental in ovo vaccination has been used for a number of diseases including Marek's disease (MD) (Sharma & Burmester, 1982;Sharma & Graham, 1982;Sharma et al, 1984), infectious bronchitis (Wakenell & Sharma, 1986;Walkenell et al, 1995), infectious bursal disease (Sharma, 1985), Newcastle disease (Ahmed & Sharma, 1992), coccidiosis (Ruff et al, 1988;Watkins et al, 1995) and a combination of diseases (Gagic et al, 1999;. However, to date, this technology is most widely used to vaccinate broiler chickens against MD (Ricks et al, 1999). The two main objectives of in ovo vaccination are: (1) to maximize the interval between vaccination and possible early natural challenge by virulent virus, allowing sufficient time for adequate vaccinal immunity to develop (Sharma & Burmester, 1982); and (2) to reduce handling of chicks and labour costs in the hatchery associated with post-hatch subcutaneous vaccination (Gildersleeve et al, 1993).…”

Section: Introductionmentioning

confidence: 99%

Influence of vaccine deposition site on post-vaccinal viraemia and vaccine efficacy in broiler chickens following in ovo vaccination against Marek's disease

Islam¹,

Walkden‐Brown²,

Wong³

et al. 2001

Avian Pathology

View full text Add to dashboard Cite

In ovo vaccination against Marek's disease is a widely used technology in the broiler industry. A series of experiments was carried out to determine the site of vaccine deposition in the egg during automated in ovo vaccination, and the effect of vaccine deposition site and dose on vaccine responses following vaccination with cell-associated herpesvirus of turkeys in commercial broiler chickens. Vaccine deposition site following automated in ovo vaccination was principally influenced by the age of embryo, with egg size having a smaller effect. The frequency of vaccine deposition inside the embryo body increased as incubation progressed from day 17.5 to 19.5. In experiments using manual vaccine deposition intra-embryonically (IE) or extra-embryonically (EE) at day 18.5, EE vaccine deposition resulted in a significantly delayed development of post-vaccinal viraemia relative to both IE vaccination and subcutaneous vaccination at hatch. There were no effects of vaccine dose (2000, 4000 or 8000 plaque forming units) on the timing of post-vaccinal viraemia. The timing of post-vaccinal viraemia was found to be a good indicator of the level of protection provided by the vaccine against challenge with earlier viraemia associated with better protection. IE vaccine deposition induced significantly greater protection than EE deposition against challenge with a virulent strain of Marek's disease virus. IE deposition consistently produced a high level of protection (68 to 84%) irrespective of vaccine dose or challenge day, while EE vaccine deposition produced no or low levels of protection (0 to 27%) depending on the vaccine dose and day of challenge. The growth of challenged chickens was also affected by site of vaccine deposition, with significantly higher live weights at day 56 of age in IE compared with EE vaccinated groups. These data suggest that the site of vaccine deposition within the embryo is an important determinant of the success of in ovo vaccination.

show abstract

“…A number of vaccination approaches such as genetically attenuated live, recombinant subunit and DNA vaccines (van den Berg, 2000) and vaccines based on immune complexes (Icx) (Whitfill et al ., 1995;Haddad et al ., 1997) have been developed to improve vaccination of maternal antibody-positive chicks. Icx vaccines consisting of a mixture of hyperimmune IBDV chicken serum (aIBDV) and an embryo-adapted live IBDV (aIBDV.IBDV) (Whitfill et al ., 1995) can be inoculated either in ovo or to 1-day old chicks (Haddad et al ., 1997;Ricks et al ., 1999;van den Wijngaard, 2001). As maternal antibodies decline below a certain level, IBDV released from the Icx infects the target cells and proceeds through the usual course of infection, stimulating antibody response and protective immunity.…”

Section: Introductionmentioning

confidence: 99%

“…In essence, each chick is vaccinated at the most appropriate time, resulting in a flock with uniform immunity and protected throughout the entire growing period. An Icx vaccine, Bursaplex † , has been marketed and is expected to replace conventional IBDV vaccination in broilers (Ricks et al ., 1999). Vaccines for other avian pathogens based on the Icx are also being developed (Ricks et al ., 1999;Guo et al ., 2003).…”

Section: Introductionmentioning

confidence: 99%

“…An Icx vaccine, Bursaplex † , has been marketed and is expected to replace conventional IBDV vaccination in broilers (Ricks et al ., 1999). Vaccines for other avian pathogens based on the Icx are also being developed (Ricks et al ., 1999;Guo et al ., 2003). Virusspecific antibodies used in the Icx are currently produced by hyperimmunization of specific pathogen free (SPF) chickens.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chicken recombinant antibodies against infectious bursal disease virus are able to form antibody–virus immune complex

et al. 2006

View full text Add to dashboard Cite

Virus particles exposed to specific anti-virus antibodies result in the formation of immune complexes (Icx). Recent vaccination strategies have employed this feature, and an infectious bursal disease virus (IBDV) vaccine based on Icx has been released and is expected to replace conventional IBDV vaccines. We evaluated whether chicken recombinant antibodies (rAb) specific for IBDV, rather than conventional chicken anti-IBDV sera, could be used to generate Icx. Out of 14 rAb expressed as soluble single-chain variable fragments (scFv), nine were able to completely neutralize Bursavac, a live IBDV vaccine, when tested in ovo. When these rAb were mixed with IBDV and inoculated into either 18-day-old embryos, or 1-day-old or 2-week-old specific pathogen free chicks, a rAb.IBDV complex was formed. These Icx were similar to those produced by polyclonal chick anti-IBDV sera and IBDV. Following inoculation of the rAb.IBDV complex, the virus was rendered non-infectious for 5 to 7 days. After this time virus was released from the Icx, resulting in infection of the inoculated chicks and subsequent induction of an immune response and protection against virulent IBDV challenge. The results indicated that genetically derived antibodies can replace polyclonal sera in the formulation of Icx vaccines.

show abstract

In Ovo Vaccination Technology *The authors are employees and consultants of Embrex, Inc., which disclaims responsibility for any private publication of its personnel. The views expressed herein do not necessarily reflect the views of Embrex, Inc. or its management.

Cited by 81 publications

References 31 publications

Comparison ofin ovoand post‐hatch vaccination with particular reference to infectious bursal disease. A review

Comparison ofin ovoand post‐hatch vaccination with particular reference to infectious bursal disease. A review

Influence of vaccine deposition site on post-vaccinal viraemia and vaccine efficacy in broiler chickens following in ovo vaccination against Marek's disease

Chicken recombinant antibodies against infectious bursal disease virus are able to form antibody–virus immune complex

Contact Info

Product

Resources

About